Gastric Inhibitory Polypeptide Receptor (GIPR) Antibody

Background

GIPR is a G-protein-coupled receptor expressed primarily on pancreatic β-cells, adipose tissue, intestinal cells, and the central nervous system, where it mediates the physiological actions of GIP Upon GIP binding, GIPR activates intracellular pathways including cAMP signaling, protein kinase A, and Epac2, leading to enhanced glucose-dependent insulin secretion from β-cells GIPR also regulates lipid metabolism in adipose tissue by increasing lipogenesis and triglyceride storage through lipoprotein lipase activation GIPR signaling in bone tissue promotes osteoblast activity and bone mineralization, supporting skeletal growth and homeostasis In the central nervous system, GIPR modulates energy balance and appetite through hypothalamic pathways Genetic variations in GIPR are linked to obesity, insulin resistance, and impaired glucose metabolism due to altered GIP signaling Pharmacological therapies targeting GIPR, including GIPR agonists and dual GIP/GLP-1 receptor agonists, are being developed to improve glucose control, reduce body weight, and treat components of metabolic syndrome